Endothelial (Dys)function in lone atrial fibrillation

Current Pharmaceutical Design

Volumn 21, Issue 5, 2015, Pages 622-645

  Polovina, Marija M ^a   Lip, Gregory Y H ^b,c   Potpara, Tatjana S ^a,c  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Asymmetric dimethylarginine; Circulating endothelial cells; E selectin; Endocardial dysfunction; Endothelial damage; Endothelial dysfunction; Endotheliumdependent vasodilatation; Flow mediated dilation; Lone atrial fibrillation; Microparticles; Progenitor endothelial cells; Thrombomodulin; Von Willebrand factor

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; N(G),N(G) DIMETHYLARGININE; THROMBOMODULIN; VON WILLEBRAND FACTOR; ARGININE; BIOLOGICAL MARKER; N,N-DIMETHYLARGININE; SELE PROTEIN, HUMAN; THBD PROTEIN, HUMAN;

ADVERSE OUTCOME; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORONARY ARTERY BLOOD FLOW; CORONARY FLOW RESERVE; ENDOCARDIUM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERCOAGULABILITY; MEMBRANE MICROPARTICLE; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASCULARIZATION; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; BLOOD; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR;

ARGININE; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; E-SELECTIN; ENDOCARDIUM; ENDOTHELIUM, VASCULAR; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; THROMBOMODULIN; VON WILLEBRAND FACTOR;

EID: 84925686997     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140825143028     Document Type: Article

References (180)

1. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534-39.
2. Valderrama AL, Dunbar SB, Mensah GA. Atrial fibrillation: public health implications. Am J Prev Med 2005; (5 Suppl 1): 29: 75-80.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983-8.
4. Gattellari M, Goumas C, Aitken R, Worthington JM. Outcomes for Patients with Ischaemic Stroke and Atrial Fibrillation: The PRISM Study (A Program of Research Informing Stroke Management). Cerebrovasc Dis 2011; 32: 370-82.
5. Odell JA, Blackshear JL, Davies E, et al. Thoracoscopic obliteration of the left atrial appendage: potential for stroke reduction? Ann Thorac Surg. 1996; 61: 565-9.
6. NM AL-Saady, OA Obel, AJ Camm. Left atrial appendage: structure, function and role in thromboembolism. Heart 1999; 82: 547-55.
7. Watson T, Shantsila E, Lip GYH. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009; 373: 155-66.
8. Freestone B, Lip GYH. The endothelium and atrial fibrillation. The prothrombotic state revisited. Hämostaseologie 2008; 28: 207-12.
9. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007; 69: 546-54.
10. Camm AJ, Lip GYH, De Caterina R, et al. 2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation. European Heart Journal 2012; 33: 2719-47.
11. Disertori M, Franzosi MG, Barlera S, et al. Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial. BMC Cardiovasc Disord. 2013; 13: 28.
12. Potpara TS, Stankovic GR, Beleslin BD, et al. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. Chest. 2012; 141: 339-47.
13. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002; 54: 230-46.
14. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995; 92: 1954-68.
15. Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur Heart J. 2013; 34: 2731-8
16. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997; 96: 1180-4.
17. Stiles MK, John B, Wong CX, et al. Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the "second factor". J Am Coll Cardiol. 2009; 53: 1182-91.
18. Mahnkopf C, Badger TJ, Burgon NS, et al. Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayedenhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm. 2010; 7: 1475-81.
19. Kottkamp H. Fibrotic atrial cardiomyopathy: a specific disease/syndrome supplying substrates for atrial fibrillation, atrial tachycardia, sinus node disease, AV node disease, and thromboembolic complications. J Cardiovasc Electrophysiol. 2012; 23: 797-9.
20. Masawa N, Yoshida Y, Yamada T, Joshita T, Ooneda G. Diagnosis of cardiac thrombosis in patients with atrial fibrillation in the absence of macroscopically visible thrombi. Virchows Arch A Pathol Anat Histopathol. 1993; 422: 67-71.
21. Shirani J, Alaeddini J. Structural remodelling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: implications for thrombus formation, systemic embolism and assessment by transesophageal echocardiography. Cardiovasc Pathol. 2000; 9: 95-101.
22. Goldsmith I, Kumar P, Carter P, Blann AD, Patel RL, Lip GYH. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J. 2000; 140: 777-84.
23. Nakamura Y, Nakamura K, Fukushima-Kusano K, et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res. 2003; 111: 137-42.
24. Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol. 2001; 37: 1436-42.
25. Radomski MW, Moncada S. Regulation of vascular homeostasis by nitric oxide. Throm Haemost. 1993; 70: 36-41.
26. Matsushita K, Morrell CN, Cambien B, et al. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell. 2003; 115: 139-50.
27. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1-R12.
28. F_rstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012: 33: 829-37.
29. Ziegler T, Bouzourene K, Harrison V, Brunner H, Hayoz D. Influence of oscillatory and unidirectional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 686-692
30. Wentzel JJ, Chatzizisis YS, Gijsen FJ, et al. Endothelial shear stress in the evolution of coronary atherosclerotic plaque and vascular re modelling: current understanding and remaining questions. Cardiovasc Res. 2012; 96: 234-43.
31. Cerveró J, Segura V, Macías A, Gavira JJ, Montes R, Hermida J. Atrial fibrillation in pigs induces left atrial endocardial transcriptional remodelling. Thromb Haemost. 2012; 108: 742-9.
32. Cai H, Li Z, Goette A, Mera F, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation. 2002; 106: 2854-8.
33. Dudley SC Jr, Hoch NE, McCann LA, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation. 2005; 112: 1266-73.
34. Kim YM, Guzik TJ, Zhang YH, et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res. 2005; 97: 629-36.
35. Chen MC, Chang JP, Liu WH, et al. Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation. Am J Cardiol. 2008; 102: 861-5.
36. Gramley F, Lorenzen J, Jedamzik B, et al. Atrial fibrillation is associated with cardiac hypoxia. Cardiovasc Pathol. 2010; 19: 102-11.
37. Kapur NK, Deming CB, Kapur S, et al. Hemodynamic modulation of endocardial thromboresistance. Circulation. 2007; 115: 67-75.
38. Cerveró J, Montes R, España F, Esmon CT, Hermida J. Limited ability to activate protein C confers left atrial endocardium a thrombogenic phenotype: a role in cardioembolic stroke? Stroke. 2011; 42: 2622-4
39. Kumagai K, Fukuchi M, Ohta J, et al. Expression of the von Willebrand factor in atrial endocardium is increased in atrial fibrillation depending on the extent of structural remodeling. Circ J. 2004; 68: 321-7.
40. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med. 1992; 116: 6-12.
41. Schwartzman D, Schoedel K, Stolz DB, Di Martino E. Morphological and mechanical examination of the atrial 'intima'. Europace. 2013; 15: 1557-61.
42. Anyukhovsky EP, Sosunov EA, Chandra P, et al. Age-associated changes in electrophysiologic remodeling: a potential contributor to initiation of atrial fibrillation. Cardiovasc Res. 2005; 66: 353-63.
43. Hemmeryckx B, Hoylaerts MF, Deloose E, et al. Age-associated pro-inflammatory adaptations of the mouse thoracic aorta. Thromb Haemost. 2013; 110: 785-94
44. Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Prostran MS, Lip GY. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol. 2012; 5: 319-26
45. Kaireviciute D, Lip GY, Balakrishnan B, et al. Intracardiac expression of markers of endothelial damage/dysfunction, inflammation, thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation. J Thromb Haemost. 2011 Dec; 9(12): 2345-52.
46. Hu YF, Chen YC, Cheng CC, Higa S, Chen YJ, Chen SA. Fluvastatin reduces pulmonary vein spontaneous activity through nitric oxide pathway. J Cardiovasc Electrophysiol. 2009; 20: 200-6.
47. Nishijima Y, Sridhar A, Bonilla I, et al. Tetrahydrobiopterin depletion and NOS2 uncoupling contribute to heart failure-induced alterations in atrial electrophysiology. Cardiovasc Res. 2011; 91: 71-9.
48. Luo GP, Ni B, Yang X, Wu YZ. von Willebrand factor: more than a regulator of hemostasis and thrombosis. Acta Haematol. 2012; 128: 158-69.
49. van Hinsbergh VWM. Endothelium-role in regulation of coagulantion and inflammation. Semin Immunopathol. 2012; 34: 93-106.
50. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor: basic aspects and application to the R1205H mutation. J Biol Chem 2004; 279: 12102-09
51. van Schooten CJ, Shahbazi S, Groot E, et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2005; 112: 1704-12.
52. Dasgupta S, Repesse Y, Bayry J, et al. vWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-612
53. Andrews RK, Berndt MC: Platelet physiology and thrombosis. Thromb Res 2004; 114: 447-453.
54. Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell 2003; 112: 87-97.
55. Cheng H, Yan R, Li S, Yuan Y, Liu J, Ruan C, Dai K. Shearinduced interaction of platelets with von Willebrand factor results in glycoprotein Ib_shedding. Am J Physiol Heart Circ Physiol 2009; 297: 2128-35.
56. Gustafsson C, Blombäck M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke. 1990; 21: 47-51.
57. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995; 73: 527-33.
58. Yamamoto K, Ikeda U, Seino Y, et al. Coagulation activity is increased in the left atrium of patients with mitral stenosis. J Am Coll Cardiol. 1995; 25: 107-12.
59. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart. 1997; 77: 407-11.
60. Li-Saw-Hee FL, Blann AD, Goldsmith I, Lip GY. Indexes of hypercoagulability measured in peripheral blood reflect levels in intracardiac blood in patients with atrial fibrillation secondary to mitral stenosis. Am J Cardiol. 1999; 83: 1206-9.
61. Goldsmith IR, Foo LS, Blann AD, Lip GY. Increased platelet activation and endothelial dysfunction in patients with atrial fibrillation immediately following percutaneous balloon mitral valvuloplasty. Clin Cardiol. 2000; 23: 587-90.
62. Li-Saw-Hee FL, Blann AD, Lip GY. Effect of degree of blood pressure on the hypercoagulable state in chronic atrial fibrillation. Am J Cardiol. 2000; 86: 795-7, A9.
63. Feng D, D'Agostino RB, Silbershatz H, et al. Hemostatic state and atrial fibrillation (the Framingham Offspring Study). Am J Cardiol. 2001; 87: 168-71.
64. Li-Saw-Hee FL, Blann AD, Lip GY.Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke. 2000; 31: 828-33.
65. Li-Saw-Hee FL, Blann AD, Gurney D, Lip GY. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J. 2001; 22: 1741-7.
66. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation. 2002; 106: 1962-7.
67. Nikitovic D, Zacharis EA, Manios EG, et al. Plasma Levels of Nitrites/Nitrates in Patients with Chronic Atrial Fibrillation are Increased after Electrical Restoration of Sinus Rhythm. J Interv Card Electrophysiol. 2002; 7: 171
68. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 2003; 107: 3141-5.
69. Conway DS, Heeringa J, Van Der Kuip DA, et al. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke. 2003; 34: 413-7.
70. Conway DS, Buggins P, Hughes E, Lip GY. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol. 2004; 93: 1368-73, A6.
71. Conway DS, Buggins P, Hughes E, Lip GY. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol. 2004 Aug 15; 94(4): 508-10.
72. Marín F, Roldán V, Climent VE, et al. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart. 2004; 90: 1162-6
73. Lip GY, Pearce LA, Chin BS, Conway DS, Hart RG. Effects of congestive heart failure on plasma von Willebrand factor and solu ble P-selectin concentrations in patients with non-valvar atrial fibrillation. Heart. 2005; 91: 759-63.
74. Roldán V, Marín F, García-Herola A, Lip GY. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb Res. 2005; 116: 321-5.
75. Freestone B, Lip GY, Chong AY, Nadar S, Lee KW, Blann AD. Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease. Thromb Haemost. 2005; 94: 702-6.
76. Freestone B, Chong AY, Lim HS, Blann A, Lip GY. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis? Ann Med. 2005; 37: 365-72.
77. Freestone B, Chong AY, Blann AD, Lip GY. The effects of direct current cardioversion for persistent atrial fibrillation on indices of endothelial damage/dysfunction. Thromb Res. 2006; 118: 479-85.
78. Heeringa J, Conway DS, van der Kuip DA, et al. A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990-1999. J Thromb Haemost. 2006; 4: 1944-9.
79. Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke. 2006; 37: 2294-300.
80. Sato M, Suzuki A, Nagata K, Uchiyama SIncreased von Willebrand factor in acute stroke patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 2006; 15: 1-7.
81. Varughese GI, Patel JV, Tomson J, Lip GYEffects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation. Heart. 2007; 93: 495-9.
82. Yip HK, Lai SL, Lan MY, et al. Time course of platelet activation and von Willebrand factor in patients with non-valvular atrial fibrillation after ischemic stroke. Circ J. 2007; 71: 321-6.
83. Freestone B, Gustafsson F, Chong AY, et al. Influence of atrial fibrillation on plasma von willebrand factor, soluble E-selectin, and N-terminal pro B-type natriuretic peptide levels in systolic heart failure. Chest. 2008; 133(5): 1203-8.
84. Kalyoncu U, Dizdar O, Erkan Duman A, et al. Alterations of von Willebrand factor and ristocetin cofactor activity during atrial fibrillation. Clin Appl Thromb Hemost. 2009; 15: 103-8.
85. Pinto A, Tuttolomondo A, Casuccio A, et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic nonvalvular atrial fibrillation (NVAF). Clin Sci (Lond). 2009; 116: 781-9.
86. Uemura T, Kaikita K, Yamabe H, et al. Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation. Thromb Res. 2009; 124: 28-32.
87. Watson T, Arya A, Sulke N, Lip GY. Relationship of indices of inflammation and thrombogenesis to arrhythmia burden in paroxysmal atrial fibrillation. Chest. 2010 Apr; 137(4): 869-76.
88. Hou J, Liang Y, Gai X, et al. The impact of acute atrial fibrillation on the prothrombotic state in patients with essential hypertension. Clin Biochem. 2010; 43: 1212-5.
89. Ammash N, Konik EA, McBane RD, et al. Left atrial blood stasis and Von Willebrand factor-ADAMTS13 homeostasis in atrial fibrillation. Arterioscler Thromb Vasc Biol. 2011; 31: 2760-6.
90. Ehrlich JR, Kaluzny M, Baumann S, Lehmann R, Hohnloser SH. Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clin Res Cardiol 2011; 100: 1029-36.
91. Kaireviciute D, Blann AD, Balakrishnan B, et al. Characterisation and validity of inflammatory biomarkers in the prediction of postoperative atrial fibrillation in coronary artery disease patients. Thromb Haemost. 2010; 104: 122-7.
92. Roldán V, Marín F, Muiña B, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011 Jun 21; 57(25): 2496-504.
93. Alonso A, Tang W, Agarwal SK, Soliman EZ, Chamberlain AM, Folsom AR. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. Int J Cardiol. 2012; 155: 217-22.
94. Freynhofer MK, Bruno V, Jarai R, Gruber S, Höchtl T, Brozovic I, Farhan S, Wojta J, Huber KLevels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation. Thromb Haemost. 2011; 105: 435-43.
95. Scridon A, Girerd N, Rugeri L, Nonin-Babary E, Chevalier P. Progressive endothelial damage revealed by multilevel von Willebrand factor plasma concentrations in atrial fibrillation patients. Europace. 2013; 15: 1562-6.
96. Krishnamoorthy S, Khoo CW, Lim HS, et al. Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation. Eur J Clin Invest. 2013; 43: 1032-8.
97. Girerd N, Scridon A, Bessière F, et al. Periatrial epicardial fat is associated with markers of endothelial dysfunction in patients with atrial fibrillation. PLoS One. 2013; 8: e77167.
98. Li-Saw-Hee FL, Blann AD, Lip GY. A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. J Am Coll Cardiol. 2000; 35: 1926-31.
99. Mondillo S, Sabatini L, Agricola E, et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol. 2000; 75: 227-32.
100. Li-Saw-Hee FL, Blann AD, Edmunds E, Gibbs CR, Lip GY. Effect of acute exercise on the raised plasma fibrinogen, soluble P-selectin and von Willebrand factor levels in chronic atrial fibrillation. Clin Cardiol. 2001; 24: 409-14.
101. Goette A, Weber M, Lendeckel U, Welte T, Lutze G, Klein HU. Effect of physical exercise on platelet activity and the von-Willebrand-factor in patients with persistent lone atrial fibrillation. J Interv Card Electrophysiol. 2004; 10: 139-46.
102. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol. 2004; 43: 2075-82.
103. Coll-Vinent B, Monteagudo J, Miró O, et al. Transient endothelial dysfunction is present shortly after cardioversion in patients with lone atrial fibrillation. Thromb Res. 2006; 117: 235-40.
104. Freestone B, Chong AY, Nuttall S, Blann AD, Lip GY. Soluble Eselectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest. 2007; 132: 1253-8.
105. Watson T, Shantsila E, Blann A, Lip GY. Circulating progenitor cells in patients with atrial fibrillation and their relation with serum markers of inflammation and angiogenesis. Thromb Haemost. 2010; 104: 327-34.
106. Fu R, Wu S, Wu P, Qiu J. A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation. Europace. 2011; 13: 31-6.
107. Feng D, D'Agostino RB, Silbershatz H, et al.Hemostatic state and atrial fibrillation (the Framingham Offspring Study). Am J Cardiol. 2001; 87: 168-71.
108. Conway EM. Thrombomodulin and its role in atrial fibrillation. Semin Immunopathol. 2012; 34: 107-125.
109. Boehme MW, Deng Y, Raeth U, et al. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology. 1996; 87: 134-40.
110. Boffa MC, Karmochkine M. Thrombomodulin: an overview and potential implications in vascular disorders. Lupus. 1998; 7 Suppl 2: S120-5.
111. Salomaa V, Matei C, Aleksic N, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet. 1999; 353: 1729-34.
112. Wu KK, Aleksic N, Ballantyne CM, Ahn C, Juneja H, Boerwinkle E. Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation. 2003; 107: 1729-32.
113. Wo_akowska-Kap_on B, Bartkowiak R, Grabowska U, Janiszewska G. Persistent atrial fibrillation is not associated with thrombomodulin level increase in efficiently anticoagulated patients. Arch Med Sci. 2010; 6: 887-91.
114. Ikuma H, Wada H, Mori Y, et al. Hemostatic markers in Japanese patients undergoing anticoagulant therapy under thrombo-test monitoring. Blood Coagul Fibrinolysis. 1999; 10: 429-34.
115. Acevedo M, Corbalán R, Braun S, Pereira J, González I, Navarrete C. Biochemical predictors of cardiac rhythm at 1 year follow-up in patients with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2012 Feb 3.
116. Chong A-Y., Blann AD, Lip GYH. Assessment of endothelial damage and dysfunction: observations in relation to heart failure. Q J Med. 2003; 96: 253-267.
117. Blann AD, Lip GY. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul Fibrinolysis. 1998; 9: 297-306.
118. Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol. 2007; 99: 1544-8.
119. Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: regulation and action. Pharmacol Res. 2009; 60: 448-60.
120. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol. 2006; 2: 209-20.
121. Welch WJ, Wilcox CS. Macula densa arginine delivery and uptake in the rat regulates glomerular capillary pressure: effects of salt intake. J Clin Invest. 1997; 100: 2235-42.
122. Pope AJ, Karuppiah K, Cardounel AJ. Role of the PRMT-DDAHADMA axis in the regulation of endothelial nitric oxide production. Pharmacol Res. 2009; 60: 461-5.
123. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999; 99: 1141-6.
124. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998; 98: 1842-7.
125. Bode-Böger SM, Scalera F, Ignarro LJ. The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther. 2007; 114: 295-306.
126. Saitoh M, Osanai T, Kamada T, et al. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessels. 2003; 18: 177-82.
127. Böger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res. 2009; 60: 481-7.
128. Cengel A, Sahinarslan A, Bibero_lu G, et al. Asymmetrical dimethylarginine level in atrial fibrillation. Acta Cardiol. 2008; 63: 33-7.
129. Xia W, Qu X, Yu Y, Zhang X, Feng W, Song Y. Asymmetric dimethylarginine concentration and early recurrence of atrial fibrillation after electrical cardioversion. Pacing Clin Electrophysiol. 2008; 31: 1036-40.
130. Xia W, Yin Z, Li J, Song Y, Qu X. Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol. 2009; 32: 1562-6.
131. Tveit A, Arnesen H, Smith P, Bratseth V, Seljeflot I. L-arginine, asymmetric dimethylarginine and rhythm outcome after electrical cardioversion for atrial fibrillation. Cardiology. 2010; 117: 176-80.
132. Yang L, Xiufen Q, Shuqin S, et al. Asymmetric dimethylarginine concentration and recurrence of atrial tachyarrythmias after catheter ablation in patients with persistent atrial fibrillation. J Interv Card Electrophysiol. 2011; 32: 147-54.
133. Goette A, Hammwöhner M, Bukowska A, et al. The impact of rapid atrial pacing on ADMA and endothelial NOS. Int J Cardiol. 2012; 154: 141-6.
134. Lim HS, Willoughby SR, Schultz C, et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. J Am Coll Cardiol. 2013; 61: 852-60.
135. Chao TF, Lu TM, Lin YJ, et al. Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. PLoS One. 2013; 8: e71675.
136. Suda O, Tsutsui M, Morishita T, et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthasedeficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol. 2004; 24: 1682-8.
137. von Leitner EC, Klinke A, Atzler D, et al. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation. 2011; 124: 2735-45.
138. Boos CJ, Lip GY, Blann AD. Circulating endothelial cells in cardiovascular disease J Am Coll Cardiol. 2006; 48: 1538-47.
139. Makin A, Chung NAY, Silverman SH, Blann A, Lip GY. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Eur Heart J 2004; 25: 371-6.
140. Nadar S, Lip GYH, Blann AD. Circulating endothelial cells in acute ischaemic stroke. Thromb Haemost 2005; 94: 707-12.
141. Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005; 105: 526-32.
142. Ravens U. Atrial fibrillation and circulating endothelial progenitor cells. Europace 2010; 12: 460-461
143. Siu CW, Watson T, Lai WH, et al. Relationship of circulating endothelial progenitor cells to the recurrence of atrial fibrillation after successful conversion and maintenance of sinus rhythm. Europace. 2010; 12: 517-21.
144. Jesel L, Abbas M, Toti F, Cohen A, Arentz T, Morel O. Microparticles in atrial fibrillation: a link between cell activation or apoptosis, tissue remodelling and thrombogenicity. Int J Cardiol. 2013; 168: 660-9.
145. Jy W, Johansen ME, Bidot C Jr, Horstman LL, Ahn YS. Red cellderived microparticles (RMP) as haemostatic agent. Thromb Haemost. 2013; 110: 751-60.
146. Leroyer AS, Anfosso F, Lacroix R, et al. Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. Thromb Haemost. 2010; 104: 456-63.
147. Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011; 31: 15-26.
148. Collier ME, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity. Thromb Haemost. 2013; 110: 966-76.
149. Collier ME, Maraveyas A, Ettelaie C. Filamin-A is required for the incorporation of tissue factor into cell-derived microvesicles. Thromb Haemost. 2013 Nov 21; 111(4).
150. Collier ME, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity. Thromb Haemost. 2013; 110: 966-76.
151. Chirinos JA, Castrellon A, Zambrano JP, et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm 2005; 2: 525-9.
152. Hayashi M, Takeshita K, Inden Y, et al. Platelet activation and induction of tissue factor in acute and chronic atrial fibrillation: involvement of mononuclear cell-platelet interaction. Thromb Res 2011; 128: e113-8.
153. Wang H, Yan HM, Tang MX, et al. Increased serum levels of microvesicles in nonvalvular atrial fibrillation determinated by ELISA using a specific monoclonal antibody AD-1. Clin Chim Acta 2010; 411: 1700-4.
154. Ederhy S, Di Angelantonio E, Mallat Z, et al. Levels of circulating procoagulant microparticles in nonvalvular atrial fibrillation. Am J Cardiol. 2007; 100: 989-94.
155. Jesel L, Arentz T, Herrera-Siklody C, et al. Do Atrial Differences in Endothelial Damage, Leukocyte and Platelet Activation, or Tissue Factor Activity Contribute to Chamber-Specific Thrombogenic Status in Patients with Atrial Fibrillation? J Cardiovasc Electrophysiol. 2013 Oct 31. doi: 10.1111/jce.12312.
156. Krishnamoorthy S, Lim SH, Lip GY. Assessment of endothelial (dys)function in atrial fibrillation. Ann Med. 2009; 41: 576-90.
157. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39: 257-65.
158. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340: 1111-5.
159. Gosselink AT, Smit AJ, Crijns HJ, Hillege HH, Lie KI. Alteration of peripheral vasodilatory reserve capacity after cardioversion of atrial fibrillation. Eur Heart J. 1996; 17: 926-34.
160. Takahashi N, Ishibashi Y, Shimada T, et al. Atrial fibrillation impairs endothelial function of forearm vessels in humans. J Card Fail. 2001; 7: 45-54.
161. Takahashi N, Ishibashi Y, Shimada T, et al. Impaired exerciseinduced vasodilatation in chronic atrial fibrillation--role of endothelium-derived nitric oxide. Circ J. 2002; 66: 583-8.
162. Guazzi M, Belletti S, Tumminello G, Fiorentini C, Guazzi MD. Exercise hyperventilation, dyspnea sensation, and ergoreflex activation in lone atrial fibrillation. Am J Physiol Heart Circ Physiol. 2004; 287: H2899-905.
163. Chlumsk I, Charvát J. Endothelial dysfunction, distensibility and intima-media thickness and aetiology of stroke. J Int Med Res. 2005; 33: 555-61.
164. Guazzi M, Belletti S, Bianco E, Lenatti L, Guazzi MD. Endothelial dysfunction and exercise performance in lone atrial fibrillation or associated with hypertension or diabetes: different results with cardioversion. Am J Physiol Heart Circ Physiol. 2006; 291: H921-8.
165. Guazzi M, Belletti S, Lenatti L, Bianco E, Guazzi MD. Effects of cardioversion of atrial fibrillation on endothelial function in hypertension or diabetes. Eur J Clin Invest. 2007; 37: 26-34.
166. Skalidis EI, Zacharis EA, Tsetis DK, et al. Endothelial cell function during atrial fibrillation and after restoration of sinus rhythm. Am J Cardiol. 2007; 99: 1258-62.
167. Freestone B, Chong AY, Nuttall S, Lip GY. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. Thromb Res. 2008; 122: 85-90.
168. Tousoulis D, Zisimos K, Antoniades C, et al. Oxidative stress and inflammatory process in patients with atrial fibrillation: the role of left atrium distension. Int J Cardiol. 2009; 136: 258-62.
169. Shin SY, Na JO, Lim HE, et al. Improved endothelial function in patients with atrial fibrillation through maintenance of sinus rhythm by successful catheter ablation. J Cardiovasc Electrophysiol. 2011 ; 22: 376-82.
170. Polovina M, Potpara T, Giga V, Stepanovi J, Ostoji M. Impaired endothelial function in lone atrial fibrillation. Vojnosanit Pregl. 2013; 70: 908-14.
171. Yoshino S, Yoshikawa A, Hamasaki S, et al. Atrial fibrillationinduced endothelial dysfunction improves after restoration of sinus rhythm. Int J Cardiol. 2013; 168: 1280-5
172. Kochiadakis GE, Skalidis EI, Kalebubas MD, Igoumenidis NE, Chrysostomakis SI, Kanoupakis EM, Simantirakis EN, Vardas PE. Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans. Eur Heart J. 2002; 23: 734-41.
173. Range FT, Schäfers M, Acil T, et al. Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation. Eur Heart J. 2007; 28: 2223-30.
174. Skalidis EI, Hamilos MI, Karalis IK, Chlouverakis G, Kochiadakis GE, Vardas PE. Isolated atrial microvascular dysfunction in patients with lone recurrent atrial fibrillation. J Am Coll Cardiol. 2008; 51: 2053-7.
175. Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardeña G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci. 2000; 902: 230-9.
176. Minamino T, Kitakaze M, Sato H, et al. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vasc Biol 1997; 17: 3191-5.
177. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001; 104: 2886-91.
178. Ellinor PT, Low A, Patton KK, Shea MA, MacRae CA. C-Reactive protein in lone atrial fibrillation. Am J Cardiol. 2006; 97: 1346-50.
179. Guazzi M, Arena R. Endothelial dysfunction and pathophysiological correlates in atrial fibrillation. Heart. 2009; 95: 102-6.
180. Heitmar R, Summers RJ. Assessing vascular function using dynamic retinal diameter measurements: a new insight on the endothelium. Thromb Haemost. 2012; 107: 1019-26.